Teva Pharmaceutical Industries (NYSE:TEVA) Sets New 52-Week High – Still a Buy?

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)’s share price hit a new 52-week high on Monday . The company traded as high as $39.72 and last traded at $39.8650, with a volume of 996783 shares trading hands. The stock had previously closed at $38.98.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Barclays upped their price target on shares of Teva Pharmaceutical Industries from $40.00 to $42.00 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. Leerink Partners started coverage on Teva Pharmaceutical Industries in a research report on Wednesday, September 9th. They set an “outperform” rating and a $45.00 price objective on the stock. Wall Street Zen cut Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Weiss Ratings downgraded Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, September 8th. Finally, UBS Group lifted their price target on Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the company a “buy” rating in a research note on Friday, September 4th. Ten analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $43.10.

Teva Pharmaceutical Industries Stock Performance

The stock’s 50 day moving average price is $35.42 and its 200 day moving average price is $33.55. The company has a debt-to-equity ratio of 1.56, a quick ratio of 0.67 and a current ratio of 0.88. The company has a market capitalization of $46.87 billion, a P/E ratio of 67.11, a price-to-earnings-growth ratio of 4.86 and a beta of 0.87.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Tuesday, June 30th. The company reported $0.02 earnings per share for the quarter. The business had revenue of $4.14 billion during the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. As a group, equities analysts expect that Teva Pharmaceutical Industries Ltd. will post 1.94 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of TEVA. Bullseye Investment Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at about $68,000. Sequoia Financial Advisors LLC boosted its holdings in Teva Pharmaceutical Industries by 12.5% in the second quarter. Sequoia Financial Advisors LLC now owns 190,940 shares of the company’s stock worth $6,469,000 after acquiring an additional 21,240 shares in the last quarter. National Pension Service grew its stake in Teva Pharmaceutical Industries by 4.9% in the second quarter. National Pension Service now owns 2,406,013 shares of the company’s stock valued at $81,516,000 after acquiring an additional 112,357 shares during the period. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD acquired a new stake in Teva Pharmaceutical Industries in the second quarter valued at approximately $33,799,000. Finally, IFP Advisors Inc increased its holdings in shares of Teva Pharmaceutical Industries by 1.1% during the second quarter. IFP Advisors Inc now owns 143,876 shares of the company’s stock valued at $4,875,000 after acquiring an additional 1,532 shares in the last quarter. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. The company develops, manufactures and markets generic medicines, innovative specialty medicines, biosimilars, over-the-counter products and active pharmaceutical ingredients. Its portfolio serves a broad range of therapeutic areas, including central nervous system disorders, respiratory conditions, migraine, oncology and movement disorders.

Teva’s specialty medicines include treatments for conditions such as multiple sclerosis, migraine and tardive dyskinesia, while its generic medicines business supplies products across numerous therapeutic categories and dosage forms.